Mesoblast Analyst Ratings
Mesoblast Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/31/2023 | 1088.81% | Cantor Fitzgerald | $23 → $17 | Maintains | Overweight |
| 08/07/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 08/04/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 08/04/2023 | 39.86% | Piper Sandler | $7 → $2 | Downgrades | Overweight → Neutral |
| 08/04/2023 | 4.9% | Chardan Capital | $2 → $1.5 | Maintains | Sell |
| 05/30/2023 | 39.86% | Chardan Capital | $2.5 → $2 | Maintains | Sell |
| 03/01/2023 | 74.83% | Chardan Capital | → $2.5 | Reiterates | → Sell |
| 02/01/2023 | 1508.39% | Cantor Fitzgerald | → $23 | Reiterates | → Overweight |
| 12/06/2022 | — | Jefferies | Downgrades | Buy → Hold | |
| 09/06/2022 | 389.51% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 06/03/2022 | 74.83% | Chardan Capital | $6.5 → $2.5 | Maintains | Sell |
| 08/31/2021 | 354.55% | Chardan Capital | $7.5 → $6.5 | Maintains | Sell |
| 04/07/2021 | — | Maxim Group | Upgrades | Hold → Buy | |
| 01/19/2021 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/22/2020 | — | Maxim Group | Downgrades | Buy → Hold | |
| 12/04/2020 | 424.48% | Chardan Capital | $5.5 → $7.5 | Downgrades | Neutral → Sell |
| 11/20/2020 | 1298.6% | HC Wainwright & Co. | $19 → $20 | Maintains | Buy |
| 10/22/2020 | 739.16% | RBC Capital | → $12 | Initiates Coverage On | → Sector Perform |
| 10/02/2020 | 1228.67% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/28/2020 | 1368.53% | HC Wainwright & Co. | $14 → $21 | Reiterates | → Buy |
| 10/22/2019 | 1508.39% | Cantor Fitzgerald | → $23 | Assumes | → Overweight |
| 01/31/2019 | 354.55% | HC Wainwright & Co. | → $6.5 | Assumes | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月31日 | 1088.81% | 康託·菲茨傑拉德 | $23→$17 | 維護 | 超重 |
| 08/07/2023 | - | Maxim集團 | 評級下調 | 購買→Hold | |
| 08/04/2023 | - | 威廉·布萊爾 | 評級下調 | 跑贏→市場表現 | |
| 08/04/2023 | 39.86% | 派珀·桑德勒 | $7→$2 | 評級下調 | 超重→中性 |
| 08/04/2023 | 4.9% | 查爾丹資本 | $2→$1.5 | 維護 | 賣 |
| 2023年05月30日 | 39.86% | 查爾丹資本 | $2.5→$2 | 維護 | 賣 |
| 03/01/2023 | 74.83% | 查爾丹資本 | →$2.5 | 重申 | →銷售 |
| 02/01/2023 | 1508.39% | 康託·菲茨傑拉德 | →$23 | 重申 | →超重 |
| 12/06/2022 | - | 傑富瑞 | 評級下調 | 購買→Hold | |
| 09/06/2022 | 389.51% | 派珀·桑德勒 | →$7 | 開始承保 | →超重 |
| 06/03/2022 | 74.83% | 查爾丹資本 | $6.5→$2.5 | 維護 | 賣 |
| 2021/08/31 | 354.55% | 查爾丹資本 | $7.5→$6.5 | 維護 | 賣 |
| 04/07/2021 | - | Maxim集團 | 升級 | 持有→購買 | |
| 2021/01/19 | - | 傑富瑞 | 評級下調 | 購買→Hold | |
| 12/22/2020 | - | Maxim集團 | 評級下調 | 購買→Hold | |
| 12/04/2020 | 424.48% | 查爾丹資本 | $5.5→$7.5 | 評級下調 | 中性→銷售 |
| 11/20/2020 | 1298.6% | HC Wainwright公司 | $19→$20 | 維護 | 買 |
| 10/22/2020 | 739.16% | 加拿大皇家銀行資本 | →$12 | 開始承保 | →行業表現 |
| 10/02/2020 | 1228.67% | HC Wainwright公司 | $21→$19 | 維護 | 買 |
| 05/28/2020 | 1368.53% | HC Wainwright公司 | $14→$21 | 重申 | →購買 |
| 2019年10月22日 | 1508.39% | 康託·菲茨傑拉德 | →$23 | 假設 | →超重 |
| 2019年01月31日 | 354.55% | HC Wainwright公司 | →$6.5 | 假設 | →購買 |
What is the target price for Mesoblast (MESO)?
中胚層(Meso)的目標價是多少？
The latest price target for Mesoblast (NASDAQ: MESO) was reported by Cantor Fitzgerald on August 31, 2023. The analyst firm set a price target for $17.00 expecting MESO to rise to within 12 months (a possible 1088.81% upside). 10 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年8月31日報道了中胚層(納斯達克：MESO)的最新目標價。這家分析公司將目標價定為17美元，預計Meso將在12個月內上漲(可能上漲1088.81%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Mesoblast (MESO)?
分析師對中胚層(Meso)的最新評級是什麼？
The latest analyst rating for Mesoblast (NASDAQ: MESO) was provided by Cantor Fitzgerald, and Mesoblast maintained their overweight rating.
中原地產(納斯達克代碼：MESO)的最新分析師評級由康託·菲茨傑拉德提供，中原地產維持增持評級。
When is the next analyst rating going to be posted or updated for Mesoblast (MESO)?
中胚層(MESO)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mesoblast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mesoblast was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Mesoblast的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。對中胚層的最後一次評級是在2023年8月31日提交的，所以你應該預計下一次評級將在2024年8月31日左右提供。
Is the Analyst Rating Mesoblast (MESO) correct?
分析師對中胚層細胞(Meso)的評級正確嗎？
While ratings are subjective and will change, the latest Mesoblast (MESO) rating was a maintained with a price target of $23.00 to $17.00. The current price Mesoblast (MESO) is trading at is $1.43, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的中胚層(Meso)評級維持不變，目標價在23.00美元至17.00美元之間。中成纖維(Meso)目前的交易價格為1.43美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。